CANN GROUP LIMITED — Capital/Financing Update 2022

Jun 1, 2022

==> picture [108 x 42] intentionally omitted <==

ASX ANNOUNCEMENT

2 June 2022

First commercial crop harvest underway at Mildura facility

2 June 2022 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) announced today that it is currently harvesting the first commercial medicinal cannabis crop at the Company’s flagship Mildura facility.

A cultivation permit for the commercial crop was issued by the Office of Drug Control ( ODC ) in March 2022 and the harvest has proceeded on schedule following the transfer of cannabis plants from Cann’s Southern facility. With this harvest underway, Cann is now actively cultivating commercial crops across all three of its licensed sites. Subsequent crops at Mildura are already progressing well through the vegetative and flowering stages, and cropping will continue on a cyclic basis.

==> picture [243 x 174] intentionally omitted <==

Plants harvested from the current crop will be trimmed and dried on-site before undergoing extraction and manufacture of medicinal cannabis products in fulfilment of Cann’s local and international commercial supply agreements.

==> picture [452 x 254] intentionally omitted <==

Above: freshly harvested flower heads are placed on a drying rack for drying in preparation for extraction and product manufacture. Top of page: A healthy cannabis flower specimen from the crop, prior to harvest.

Cann Group Limited (ACN 603 949 739) 4 Research Avenue, Bundoora, VIC 3083 Australia Ph: +61 3 9095 7088

==> picture [78 x 31] intentionally omitted <==

Cann’s CEO, Mr Peter Crock said “The first commercial harvest at our Mildura site is a significant achievement for the Company. This harvest is just the first of many to come, but it marks the next phase in Cann’s activities as we begin to reap the benefits of our fixed infrastructure investments.”

==> picture [452 x 120] intentionally omitted <==

Above: the first tables of plants are moved into the processing room to be harvested.

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Matthew Wright NWR Communications +61 451 896 420 matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock Deborah Ambrosini CEO CFO Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 contact@canngrouplimited.com deborah.ambrosini@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved export markets. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and a state-of-the-art large-scale cultivation and manufacturing facility near Mildura, Victoria. Cann Group’s leading position in plant genetics, breeding, extraction, analysis and production techniques supports its objective to supply high quality, safe medicinal cannabis for a range of diseases and medical conditions. Cann’s product portfolio incorporates its proprietary Satipharm delivery system for cannabinoids.

Learn more at: www.canngrouplimited.com | www.satipharm.com

2